Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 13/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 13/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.37 |
| ▸ | CHRNB3 | Q05901 | 8/20 | 0.37 |
| ▸ | CHRNA6 | Q15825 | 8/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21087797 | 0.82 | HSD11B1 (0.54) | HSD11B1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL16727340 | 0.81 | HSD11B1 (0.51) | HSD11B1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL19738916 | 0.78 | CHRNB2 (0.41) | HSD11B1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL17886541 | 0.76 | APLNR (0.42) | HSD11B1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL19735106 | 0.73 | PIK3CD (0.37) | HSD11B1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL17815918 | 0.73 | CHRNB2 (0.37) | HSD11B1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24492120 | 0.72 | CHRNB2 (0.43) | HSD11B1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24492119 | 0.72 | CHRNB2 (0.43) | HSD11B1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL15298469 | 0.70 | ATM (0.38) | HSD11B1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL19712361 | 0.70 | CYP2D6 (0.36) | HSD11B1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10730880-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10189845-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | HSD11B1 1765/4885CHRNB2 4867/4885CHRNA3 4736/4885 |
| US-10730880-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | JAK1, JAK3, JAK2 | HSD11B1 1765/4885CHRNB2 4867/4885CHRNA3 4736/4885 |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | HSD11B1 1765/4885CHRNB2 4867/4885CHRNA3 4736/4885 |
| US-10189845-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | JAK1, JAK3, JAK2 | HSD11B1 1765/4885CHRNB2 4867/4885CHRNA3 4736/4885 |
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | JAK1, JAK3, JAK2 | HSD11B1 1765/4885CHRNB2 4867/4885CHRNA3 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.